NCT06994897View on ClinicalTrials.gov

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

December 8, 2027

Study Completion Date

December 8, 2027

Conditions
Healthy
Interventions
DRUG

PF-07985631

Experimental Pfizer compound which will be SC or IV

DRUG

Placebo

Placebo which will be SC or IV

Trial Locations (1)

B-1070

RECRUITING

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06994897 - A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults | Biotech Hunter | Biotech Hunter